

# Exhibit U

**In Re:**  
*Digitek*

---

*Terri-Lee Nataline, Esquire*  
*December 14, 2009*  
*Confidential – Subject to Further Confidentiality Review*

---

*GOLKOW TECHNOLOGIES, INC.*  
*Excellence In Court Reporting For Over 20 Years*  
*877.370.3377*  
*deps@golkow.com*

Original File tn121409.txt  
Min-U-Script® with Word Index

Digitek

Confidential – Subject to Further Confidentiality Review

Terri-Lee Nataline, Esquire  
December 14, 2009

<p style="text-align: right;">Page 13</p> <p>1 beyond the Bachelor degree?</p> <p>2 A No.</p> <p>3 Q And when did you get your</p> <p>4 undergraduate degree?</p> <p>5 A '92, 1992.</p> <p>6 Q From what institution?</p> <p>7 A University of Delaware.</p> <p>8 Q So you went to work for Purepac</p> <p>9 directly out of your undergraduate program?</p> <p>10 A Yes.</p> <p>11 Q Worked for them for eight years and</p> <p>12 then -- or actually worked for them about six</p> <p>13 or seven years and then went to law school;</p> <p>14 correct?</p> <p>15 A Well, I went to law school while I</p> <p>16 was working at Purepac.</p> <p>17 Q When did you start law school?</p> <p>18 A 1996.</p> <p>19 Q Were you going at night?</p> <p>20 A Yes.</p> <p>21 Q So you went to law school from 1996</p> <p>22 to 2001?</p> <p>23 A I graduated in 2000. It was four</p> <p>24 years.</p>	<p style="text-align: right;">Page 15</p> <p>1 work?</p> <p>2 A Four years.</p> <p>3 Q And then after that, what did you</p> <p>4 do?</p> <p>5 A I joined Alharma.</p> <p>6 Q So that would have been in 2004?</p> <p>7 A It was October 2004.</p> <p>8 Q And what kind of work did you</p> <p>9 initially do with Alharma?</p> <p>10 A Intellectual property.</p> <p>11 Q Okay. So there you were</p> <p>12 representing Alharma in any cases they had</p> <p>13 involving patent infringement?</p> <p>14 A That's correct.</p> <p>15 Q And for how long did you do that</p> <p>16 kind of work?</p> <p>17 A Until August 2008.</p> <p>18 Q Now, during the time that you worked</p> <p>19 in -- after you got out of law school and</p> <p>20 during the time that you worked in patent</p> <p>21 litigation either for the law firm or for</p> <p>22 Alharma, did you have or receive any medical</p> <p>23 training?</p> <p>24 A No.</p>
<p style="text-align: right;">Page 14</p> <p>1 Q And then what did you do after you</p> <p>2 got out of law school?</p> <p>3 A I joined a law firm.</p> <p>4 Q What's the name of the law firm?</p> <p>5 A Frommer Lawrence &amp; Haug.</p> <p>6 Q How big a firm was that?</p> <p>7 A At the time it was approximately 40</p> <p>8 attorneys.</p> <p>9 Q And what kind of law did you</p> <p>10 practice there?</p> <p>11 A Intellectual property.</p> <p>12 Q So that's copyrights, trademarks,</p> <p>13 patents?</p> <p>14 A Primarily patents.</p> <p>15 Q And what kind of patent work were</p> <p>16 you doing?</p> <p>17 A I was involved in litigations for</p> <p>18 pharmaceutical companies.</p> <p>19 Q So you actually represented</p> <p>20 pharmaceutical companies suing other</p> <p>21 pharmaceutical companies over patent</p> <p>22 infringements?</p> <p>23 A That's correct.</p> <p>24 Q And how long did you do that kind of</p>	<p style="text-align: right;">Page 16</p> <p>1 Q As we sit here today, did you have</p> <p>2 any medical training outside of working for</p> <p>3 pharmaceutical companies in intellectual</p> <p>4 property litigation?</p> <p>5 A No.</p> <p>6 Q Okay. Describe for me the</p> <p>7 organization of the regulatory affairs</p> <p>8 department as of the time you started working</p> <p>9 for Actavis in the regulatory affairs</p> <p>10 department as vice president in 2008.</p> <p>11 Let me back up a second and ask</p> <p>12 another question. You said you worked in</p> <p>13 intellectual property for Alharma, and then</p> <p>14 they were acquired by Actavis; correct?</p> <p>15 A That's correct.</p> <p>16 Q And you continued to do intellectual</p> <p>17 property work after the acquisition?</p> <p>18 A Yes.</p> <p>19 Q And then in August of 2008 is when</p> <p>20 you took your current position of vice</p> <p>21 president of regulatory affairs and medical</p> <p>22 affairs?</p> <p>23 A Yes.</p> <p>24 Q So you have two different</p>

Digitek

Confidential - Subject to Further Confidentiality Review

Terri-Lee Natalie, Esquire  
December 14, 2009

<p style="text-align: right;">Page 17</p> <p>1 departments reporting to you?</p> <p>2 A Yes.</p> <p>3 Q Okay. I want to talk about each of</p> <p>4 those. Tell me about the organization of the</p> <p>5 regulatory affairs department as of the time</p> <p>6 that you took over.</p> <p>7 A The group was -- there are several</p> <p>8 groups representing each of the US entities.</p> <p>9 So we had a regulatory group that handled</p> <p>10 regulatory matters for Actavis Elizabeth, a</p> <p>11 group that represented matters for Actavis</p> <p>12 Mid-Atlantic, another group responsible for</p> <p>13 Actavis Totowa, and finally a group</p> <p>14 responsible for Actavis South Atlantic.</p> <p>15 Q I'm sorry. I didn't hear the last</p> <p>16 one.</p> <p>17 A Actavis South Atlantic. It's an</p> <p>18 entity down in Florida.</p> <p>19 Q Okay. How do you spell the first</p> <p>20 part before you said Atlantic? What was that?</p> <p>21 A South.</p> <p>22 Q South?</p> <p>23 A South, S-O-U-T-H.</p> <p>24 Q Sure, got it. So each of those</p>	<p style="text-align: right;">Page 19</p> <p>1 A That's correct.</p> <p>2 Q Now, the Totowa group, how many</p> <p>3 facilities did they cover?</p> <p>4 A It would be the three facilities.</p> <p>5 Q Okay. That was Riverview, Taft, and</p> <p>6 Little Falls?</p> <p>7 A Yes.</p> <p>8 Q And the South Atlantic had one</p> <p>9 facility; is that correct?</p> <p>10 A Yes.</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 Q -- some manager?</p> <p>19 A Yes.</p> <p>20 Q Who was the director for the Totowa</p> <p>21 group?</p> <p>22 A There was not a director. There was</p> <p>23 a manager.</p> <p>24 Q Okay. Who was the manager?</p>
<p style="text-align: right;">Page 18</p> <p>1 different Actavis plants had a regulatory</p> <p>2 group?</p> <p>3 A Yes. They weren't necessarily</p> <p>4 plants. In some instances, there were several</p> <p>5 facilities. For example, the Mid-Atlantic</p> <p>6 group had three facilities.</p> <p>7 Q Okay. So there was a regulatory</p> <p>8 group for those three facilities?</p> <p>9 A Uh-huh.</p> <p>10 Q The Elizabeth group, that was in</p> <p>11 Elizabeth, New Jersey?</p> <p>12 A Yes.</p> <p>13 Q And was that for one facility?</p> <p>14 A They handled filings for Elizabeth</p> <p>15 as well as some third-party filings.</p> <p>16 Q Okay. When you say "third-party</p> <p>17 filings," what are you talking about?</p> <p>18 A They would be products developed and</p> <p>19 manufactured for Actavis Elizabeth by a</p> <p>20 company that's not owned by Actavis.</p> <p>21 Q Okay. So they had the reporting</p> <p>22 requirements for a drug manufactured for</p> <p>23 Actavis but according to the Actavis</p> <p>24 specifications?</p>	<p style="text-align: right;">Page 20</p> <p>1 A Augustine Frimpong, F-R-I-M-P-O-N-G.</p> <p>2 Q How about for the Elizabeth group;</p> <p>3 who was the manager or director there?</p> <p>4 A Janak Jadeja.</p> <p>5 Q How do you spell that one?</p> <p>6 A J-A-N-A-K J-A-D-E-J-A.</p> <p>7 Q How about for the Mid-Atlantic</p> <p>8 group?</p> <p>9 A Betsy Trowbridge.</p> <p>10 Q T-R-O-W-B-R-I-D-G-E?</p> <p>11 A Yes.</p> <p>12 Q How about the South Atlantic</p> <p>13 facility?</p> <p>14 A Monique Weitz.</p> <p>15 Q Is that W-E-I-T-Z?</p> <p>16 A Yes.</p> <p>17 Q Now, the medical affairs group when</p> <p>18 you arrived in August of 2008, how was that</p> <p>19 organized?</p> <p>20 A There is a director.</p> <p>21 Q Is this a director for the entire</p> <p>22 United States for Actavis?</p> <p>23 A Yes.</p> <p>24 Q And who was the director of medical</p>

Digitek

Confidential – Subject to Further Confidentiality Review

Terri-Lee Natalie, Esquire  
December 14, 2009

<p style="text-align: right;">Page 21</p> <p>1 affairs when you arrived?</p> <p>2 A Sarita Thapar.</p> <p>3 Q That's T-H-A-P-A-R?</p> <p>4 A Yes.</p> <p>5 Q And how many employees reported up</p> <p>6 through Sarita Thapar?</p> <p>7 A Eight or nine.</p> <p>8 Q Okay. And where was Sarita located?</p> <p>9 A In Elizabeth.</p> <p>10 Q Before you became director of</p> <p>11 regulatory and medical affairs, where was your</p> <p>12 office at Actavis?</p> <p>13 A I wasn't director.</p> <p>14 Q I'm sorry. Before you became vice</p> <p>15 president of regulatory affairs and medical</p> <p>16 affairs, where was your office with Actavis?</p> <p>17 A Elizabeth.</p> <p>18 Q Were all of the management employees</p> <p>19 located there?</p> <p>20 A I'm sorry?</p> <p>21 Q Were all the business management</p> <p>22 people for Actavis located in Elizabeth?</p> <p>23 A No.</p> <p>24 Q Well, explain to me how the company</p>	<p style="text-align: right;">Page 23</p> <p>1 Q He was?</p> <p>2 A Yes.</p> <p>3 Q You don't know what his position</p> <p>4 was?</p> <p>5 A No. It -- the titles changed</p> <p>6 frequently during that time.</p> <p>7 Q Tell me what other titles changed at</p> <p>8 that time.</p> <p>9 MR. ANDERTON: Objection.</p> <p>10 You may answer.</p> <p>11 THE WITNESS: With respect to</p> <p>12 whom?</p> <p>13 BY MR. BLIZZARD:</p> <p>14 Q With respect to anybody you knew in</p> <p>15 management.</p> <p>16 A I believe Divya at one point was</p> <p>17 president of Actavis. Then he was -- he had</p> <p>18 some responsibility for R&amp;D. At one point</p> <p>19 Doug Boothe was -- I think he was an executive</p> <p>20 vice president and chief operating officer.</p> <p>21 It was a fluid time. There were two</p> <p>22 to three individuals that were managing the</p> <p>23 Actavis US business.</p> <p>24 Q What was the reason why it was a</p>
<p style="text-align: right;">Page 22</p> <p>1 was organized in terms of office locations.</p> <p>2 Where was the CEO located?</p> <p>3 MR. ANDERTON: Objection.</p> <p>4 You may answer.</p> <p>5 THE WITNESS: It depends on the</p> <p>6 time frame.</p> <p>7 BY MR. BLIZZARD:</p> <p>8 Q Well, when you arrived, where was</p> <p>9 the CEO of Actavis Totowa located?</p> <p>10 MR. ANDERTON: Objection.</p> <p>11 You may answer.</p> <p>12 THE WITNESS: I don't believe</p> <p>13 there was a CEO of Actavis Totowa.</p> <p>14 BY MR. BLIZZARD:</p> <p>15 Q So when you arrived in August of</p> <p>16 2008, there was no CEO of Actavis Totowa?</p> <p>17 A I don't believe so.</p> <p>18 Q Was Divya Patel a CEO of Actavis,</p> <p>19 Actavis Totowa, at some point in time?</p> <p>20 A I don't know.</p> <p>21 Q Was he still employed by Actavis</p> <p>22 when you arrived as vice president of</p> <p>23 regulatory and medical affairs?</p> <p>24 A He was employed at Actavis.</p>	<p style="text-align: right;">Page 24</p> <p>1 fluid time when you arrived?</p> <p>2 MR. ANDERTON: Objection.</p> <p>3 You may answer.</p> <p>4 THE WITNESS: I think it was</p> <p>5 just a function of Actavis acquiring</p> <p>6 several entities in a short period of</p> <p>7 time.</p> <p>8 BY MR. BLIZZARD:</p> <p>9 Q Okay. So when you arrived, your</p> <p>10 understanding of why there was a fluidity of</p> <p>11 the positions of various people had to do with</p> <p>12 the Actavis acquisition?</p> <p>13 A Yes.</p> <p>14 Q And the Actavis acquisition started</p> <p>15 when?</p> <p>16 A The acquisitions in the US?</p> <p>17 Q Yes.</p> <p>18 A They acquired Amide first. I don't</p> <p>19 recall when that occurred, followed by</p> <p>20 Alpha.</p> <p>21 Q And they acquired Alpha you said</p> <p>22 when?</p> <p>23 A Say 2005. It was thereabouts.</p> <p>24 Q And didn't they acquire Amide</p>

Digitek

Confidential – Subject to Further Confidentiality Review

Terri-Lee Nataline, Esquire  
December 14, 2009

<p style="text-align: right;">Page 25</p> <p>1 shortly before that?</p> <p>2 A I believe so.</p> <p>3 Q Okay. So is it possible that was</p> <p>4 also in 2005?</p> <p>5 A I don't know.</p> <p>6 Q So as of 2008, the positions at the</p> <p>7 company following those acquisitions were</p> <p>8 still fluid; correct?</p> <p>9 A Yes.</p> <p>10 Q Was there a lot of turnover?</p> <p>11 A I don't know.</p> <p>12 Q Were any of the key positions in the</p> <p>13 company turning over when you arrived in</p> <p>14 August of 2008?</p> <p>15 MR. ANDERTON: Objection.</p> <p>16 You may answer.</p> <p>17 THE WITNESS: I don't know.</p> <p>18 There were a few exits.</p> <p>19 BY MR. BLIZZARD:</p> <p>20 Q Who were the few exits that you're</p> <p>21 aware of?</p> <p>22 A The exits would be individuals who</p> <p>23 had responsibility -- I'm sorry. What time</p> <p>24 frame? 2008?</p>	<p style="text-align: right;">Page 27</p> <p>1 those filings to support the ongoing business.</p> <p>2 Q What is an ANDA?</p> <p>3 A An abbreviated new drug application.</p> <p>4 Q And then does that require that you</p> <p>5 file follow-up periodic reports with the FDA?</p> <p>6 A It requires that we file annual</p> <p>7 reports.</p> <p>8 Q So you don't have to file quarterly</p> <p>9 reports?</p> <p>10 A The medical affairs group files</p> <p>11 periodic reports.</p> <p>12 Q But the regulatory affairs group</p> <p>13 files annual reports?</p> <p>14 A Yes.</p> <p>15 Q Any other reporting requirements</p> <p>16 other than the annual report for an ANDA?</p> <p>17 A Annual reports are required once the</p> <p>18 ANDA is approved.</p> <p>19 Q And there was an ANDA for Digitek,</p> <p>20 wasn't there?</p> <p>21 A Yes.</p> <p>22 Q Do you know when the ANDA was</p> <p>23 approved by FDA?</p> <p>24 A No.</p>
<p style="text-align: right;">Page 26</p> <p>1 BY MR. BLIZZARD:</p> <p>2 Q When you arrived,</p> <p>3 A When you say "arrived," I was, I</p> <p>4 guess, always with Actavis.</p> <p>5 Q I'm sorry. I'll make it clear.</p> <p>6 When you arrived in your current position,</p> <p>7 August 14th of 2008, who were the exits that</p> <p>8 you were aware of?</p> <p>9 A Jasmine Shah, Divya Patel, Steinthor</p> <p>10 Palsson.</p> <p>11 Q Excuse me?</p> <p>12 A Steinthor Palsson.</p> <p>13 Q How do you spell his last name?</p> <p>14 A P-A-U-L-S-S-O-N.</p> <p>15 Q Is that it?</p> <p>16 A Those were the significant changes</p> <p>17 that I recall.</p> <p>18 Q Okay. Well, we'll talk about some</p> <p>19 of the details of that later. Tell me the</p> <p>20 function first of the regulatory affairs</p> <p>21 department when you arrived in August of 2008.</p> <p>22 A The function is to oversee ANDA</p> <p>23 filings with FDA and to submit the requisite</p> <p>24 supplements, annual reports, amendments to</p>	<p style="text-align: right;">Page 28</p> <p>1 Q Do you know -- are you familiar with</p> <p>2 any of the annual reports for the Digitek</p> <p>3 ANDA?</p> <p>4 A I'm familiar with one.</p> <p>5 Q Which one?</p> <p>6 A It would have been the last one,</p> <p>7 2008's annual report.</p> <p>8 Q Okay. When was that filed with FDA?</p> <p>9 A I don't recall exactly.</p> <p>10 Q Was it timely filed?</p> <p>11 A Yes.</p> <p>12 Q What was the function of the medical</p> <p>13 affairs group when you arrived in August of</p> <p>14 2008?</p> <p>15 A They intake calls from consumers,</p> <p>16 pharmacists. We call them reporters. They</p> <p>17 intake adverse drug events, product</p> <p>18 complaints, record them, and submit them to</p> <p>19 FDA.</p> <p>20 Q Are you involved with the</p> <p>21 submission?</p> <p>22 A No.</p> <p>23 Q How often do they submit their</p> <p>24 adverse event reports to FDA?</p>